We are live on
!
Find out more
Pacer Advisors Portfolio holdings
AUM
$35.6B
1-Year Est. Return
18.19%
This Fund
S&P 500
This Quarter
Est. Return
+6.36%
1 Year Est. Return
+18.19%
3 Year Est. Return
+46.13%
5 Year Est. Return
+70.99%
10 Year Est. Return
+394.12%
AUM
$5.75B
AUM Growth
+$430M
(+8.1%)
Cap. Flow
-$1.1B
Cap. Flow
% of AUM
-19.08%
Top 10 Holdings %
Top 10 Hldgs %
27.15%
Holding
1,587
New
76
Increased
378
Reduced
937
Closed
183
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Newmont
NEM
|
+$6.27M |
| 2 |
TJX Companies
TJX
|
+$5.89M |
| 3 |
General Mills
GIS
|
+$5.87M |
| 4 |
HP
HPQ
|
+$5.84M |
| 5 |
Ford
F
|
+$5.38M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$16.7M |
| 2 |
Amazon
AMZN
|
+$14.9M |
| 3 |
Iron Mountain
IRM
|
+$14.6M |
| 4 |
Microsoft
MSFT
|
+$12.9M |
| 5 |
GDS Holdings
GDS
|
+$9.75M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Real Estate | 17.47% |
| 2 | Technology | 14.6% |
| 3 | Consumer Discretionary | 9.29% |
| 4 | Healthcare | 7.36% |
| 5 | Communication Services | 6.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1301
Kymera Therapeutics
KYMR
$8.73B
| $47K | ﹤0.01% |
+1,208
| New | +$72.7K |
|
1302
Nkarta
NKTX
$159M
| $47K | ﹤0.01% |
1,429
+914
| +177% | +$43.7K |
|
1303
AnaptysBio
ANAB
$1.54B
| $46K | ﹤0.01% |
2,122
+510
| +32% | +$12.9K |
|
1304
Coupang
CPNG
$27.7B
| $46K | ﹤0.01% |
+934
| New | +$43.2K |
|
1305
Krystal Biotech
KRYS
$10.7B
| $46K | ﹤0.01% |
602
-6
| -1% | -$436 |
|
1306
Protagonist Therapeutics
PTGX
$8.8B
| $46K | ﹤0.01% |
1,780
-178
| -9% | -$4.5K |
|
1307
Aldeyra Therapeutics
ALDX
$95.3M
| $45K | ﹤0.01% |
+3,810
| New | +$43.9K |
|
1308
Quince Therapeutics
QNCX
$18.9M
| $45K | ﹤0.01% |
6
| – | – |
|
1309
Companhia Siderúrgica Nacional
SID
$1.46B
| $45K | ﹤0.01% |
6,678
+2,716
| +69% | +$17.1K |
|
1310
Alaunos Therapeutics
TCRT
$4.64M
| $45K | ﹤0.01% |
84
+9
| +12% | +$5.6K |
|
|
SPPI
1311
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
| $45K | ﹤0.01% |
13,670
+540
| +4% | +$1.94K |
|
1312
Imperial Oil
IMO
$60.8B
| $44K | ﹤0.01% |
1,803
-95
| -5% | -$2.1K |
|
|
DMTK
1313
DELISTED
DermTech, Inc. Common Stock
DMTK
| $44K | ﹤0.01% |
+860
| New | +$45K |
|
|
RDUS
1314
DELISTED
Radius Health, Inc.
RDUS
| $43K | ﹤0.01% |
2,050
-962
| -32% | -$20.3K |
|
1315
Anavex Life Sciences
AVXL
$238M
| $42K | ﹤0.01% |
+2,786
| New | +$30.4K |
|
1316
CEMIG Preferred Shares
CIG
$6.21B
| $42K | ﹤0.01% |
34,654
+13,190
| +61% | +$16.9K |
|
1317
Vaxcyte
PCVX
$7.88B
| $42K | ﹤0.01% |
2,122
+850
| +67% | +$21.4K |
|
|
AGEN
1318
Agenus
AGEN
$275M
| $41K | ﹤0.01% |
777
-12
| -2% | -$867 |
|
1319
C4 Therapeutics
CCCC
$393M
| $41K | ﹤0.01% |
+1,096
| New | +$43.6K |
|
|
CYBR
1320
DELISTED
CyberArk
CYBR
| $41K | ﹤0.01% |
314
-15
| -5% | -$2.27K |
|
|
KLRS
1321
Kalaris Therapeutics
KLRS
$79.5M
| $41K | ﹤0.01% |
76
+35
| +85% | +$29.4K |
|
|
ALBO
1322
DELISTED
Albireo Pharma Inc
ALBO
| $41K | ﹤0.01% |
1,151
+82
| +8% | +$3.03K |
|
1323
Enanta Pharmaceuticals
ENTA
$367M
| $39K | ﹤0.01% |
798
-366
| -31% | -$18.3K |
|
1324
Oric Pharmaceuticals
ORIC
$1.23B
| $39K | ﹤0.01% |
+1,572
| New | +$49.7K |
|
1325
Gossamer Bio
GOSS
$100M
| $38K | ﹤0.01% |
4,059
+506
| +14% | +$5.1K |
|
Similar funds
SAM
Pacer Advisors's Q1 2021 Portfolio in Review
As of Q1 2021, Pacer Advisors held 1,587 positions worth $5.75B, up 8.1% from $5.32B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Pacer Advisors withdrew a net $1.1B in Q1 2021, closing 183 positions and reducing 937 holdings. Its most notable exit was Rithm Capital, an estimated $4.39M position sold in full.
By sector, the portfolio is most concentrated in Real Estate at 17% of assets, down from 18% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Pacer Advisors opened a new position in Aerojet Rocketdyne Holdings worth $3.39M.
- Pacer Advisors's largest Q1 2021 buy was Aerojet Rocketdyne Holdings: 72,150 shares worth $3.39M.
- Pacer Advisors added most to Newmont in Q1 2021, an estimated $6.27M increase.
- Pacer Advisors's biggest Q1 2021 reduction was Apple, cutting an estimated $16.7M.
- Pacer Advisors fully exited Rithm Capital in Q1 2021, selling an estimated $4.39M.
- Pacer Advisors's ten largest holdings make up 27% of its $5.75B portfolio in Q1 2021.
- Pacer Advisors opened 76 new positions and closed 183 in Q1 2021.
- Pacer Advisors's portfolio value rose 8.1% quarter-over-quarter to $5.75B.
Based on Pacer Advisors's 13F filing for Q1 2021, filed 5 Apr 2021.